Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer

Gastric Cancer. 2022 Nov;25(6):1123-1124. doi: 10.1007/s10120-022-01320-x. Epub 2022 Jul 2.

Authors

C Morelli^#¹, V Formica^#², M Roselli², H T Arkenau³

Affiliations

¹ Medical Oncology Unit and PhD Program in Systems and Experimental Medicine (XXXV Cycle), Tor Vergata University Hospital, Viale Oxford, 81, 00133, Rome, Italy. cristina.morelli89@gmail.com.
² Medical Oncology Unit and PhD Program in Systems and Experimental Medicine (XXXV Cycle), Tor Vergata University Hospital, Viale Oxford, 81, 00133, Rome, Italy.
³ Drug Development Unit, Sarah Cannon Research Institute UK, London, UK.

^# Contributed equally.

PMID: 35779127
DOI: 10.1007/s10120-022-01320-x

No abstract available

Publication types

Letter
Comment

MeSH terms

B7-H1 Antigen / metabolism
Body Composition
Esophagogastric Junction / pathology
Humans
Programmed Cell Death 1 Receptor
Stomach Neoplasms* / drug therapy
Stomach Neoplasms* / pathology

Substances

B7-H1 Antigen
Programmed Cell Death 1 Receptor